Skip to content
Menu

XORTX Therapeutics Inc. XRTX

Full chart Compare
Set alert

Price alert · XRTX

All alert types
0.84 USD -0.05 (-5.73%)

Regular-session close

0.84 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

0.8101 Day range 0.878
0.839 52-week range 3.24
YTD
-70.14%
1 year
-68.22%

5D +0.12 (+12.74%)

0.8011.201.40TueThuMon1.04
Market cap
1.88M
EPS (ttm)
-2.09
Shares out
3.22M
Forward P/E
-0.67
YTD return
-70.14%
1-year return
-68.22%
50-day average
1.37
Volume
47.88K
Avg volume
775.76K
Open
0.878
Previous close
0.89
Day's range
0.8101 – 0.878
52-week range
0.839 – 3.24
Beta
-0.21

Key statistics

200-day average
2.14
Enterprise value
744.15K
Price / book
0.48
Free cash flow
-1.85M
Total cash
3.08M
Total debt
83.71K
Return on equity
-29.36%
Short % of float
0.07%

Fundamental scorecard

6 of 25 checks passed on XRTX’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
XRTX Revenue — quarterly 0
XRTX Net income — quarterly -382.10K
XRTX EPS — quarterly -0.21

Earnings

XRTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 20240.00-0.20——
Aug 14, 2024Jun 1, 20240.000.06——
May 15, 2024Mar 1, 20240.00-1.24——
Apr 2, 2024Dec 1, 20230.00-0.48——
Nov 14, 2023Sep 1, 20230.00-6.03——
Aug 14, 2023Jun 1, 20230.00-0.81——

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.

Sector
Healthcare
Industry
Biotechnology
Country
Canada
Website
xortx.com

News

Your note

Sign in to keep a note on XRTX — it syncs with the Stock Master app.

Insider holders

XRTX insider holders
InsiderRelationLatest transactionDateShares held
Davidoff, Allen WarrenDirector of IssuerAcquisition or disposition in the public marketNov 10, 2022440,917
Keshri (Amar Deep)Senior Officer of IssuerAcquisition or disposition in the public marketDec 1, 20218,500
MacDonald (David)Senior Officer of IssuerOpening Balance-Initial SEDI ReportJan 19, 202220,000
Pratt (Raymond Dennis M.D.)Director of IssuerOpening Balance-Initial SEDI ReportJan 11, 20220

Institution ownership

XRTX institution ownership
Holder% heldSharesValueReported
UBS Group AG0.54%18,78021.03KSep 29, 2024
National Bank of Canada/FI0.10%3,4403.85KSep 29, 2024
Osaic Holdings Inc0.03%1,1531.29KSep 29, 2024
Royal Bank of Canada0.02%672752Sep 29, 2024
JP Morgan Chase & Company0.01%254284Sep 29, 2024
Clearstead Advisors, LLC0.01%277310Sep 29, 2024